Country
United Kingdom
A new UK-based company has been launched to explore the dark matter of the genome with the goal of identifying antigens for the development of off-the-shelf cancer vaccines and T cell receptor based immunotherapies.
Full text available to subscribers only. Click here for information on subscribing to MedNous.